6 CT-868, an investigational, once-daily, subcutaneously injected dual GLP-1/GIP receptor agonist currently in Phase II with the potential to be a first in class treatment for glycaemic control as an adjunct to insulin in patients living with type 1 diabetes
Dietary polyphenols and non-alcoholic fatty liver disease
GLP-1 agonists can reduce plasminogen activator inhibitor (PAI)1 levels, thereby augmenting fibrinolytic potential [96, 97]
Research shows that GLP-1 receptor agonists maintain their mechanism for several days after administration, but consistency optimizes efficacy
Supporting gut barrier integrity: Some probiotics, like Akkermansia Probiotic, may help support the gut barrier and the body's response to everyday oxidative stress
You can check if your BCBS plan covers Zepbound by following these steps: Review your policy documents: Carefully review your BCBS plan documents or member handbook for specific details on prescription drug coverage for weight loss drugs including Zepbound